Literature DB >> 15731173

Intronic splicing of hyaluronan synthase 1 (HAS1): a biologically relevant indicator of poor outcome in multiple myeloma.

Sophia Adamia1, Tony Reiman, Mary Crainie, Michael J Mant, Andrew R Belch, Linda M Pilarski.   

Abstract

In this study, we show that the hyaluronan synthase 1 (HAS1) gene undergoes aberrant intronic splicing in multiple myeloma (MM). In addition to HAS1 full length (HAS1(FL)), we identify 3 novel splice variants of HAS1, HAS1Va, HAS1Vb, and HAS1Vc, detected in patients with MM or monoclonal gammopathy of undetermined significance (MGUS). HAS1Vb and HAS1Vc undergo intronic splicing with creation of a premature stop codon. MM cells expressing one or more HAS1 variants synthesize extracellular and/or intracellular hyaluronan (HA). Expression of the HAS1Vb splice variant was significantly correlated with reduced survival (P = .001). Together, alternative HAS1 gene splicing, the correlations between HAS1 splicing and HA synthesis, and the correlations between HAS1 splicing and reduced survival of MM patients support the hypothesis that the family of HAS1 protein plays a significant role in disease progression. Further, expression of HAS1Vb, in conjunction with HAS1(FL) and/or other HAS1 variants, may lead to accumulation of intracellular HA molecules and an impact on receptor for HA-mediated motility (RHAMM)-mediated mitotic abnormalities in MM. This study highlights the potential importance of HAS1 and its alternative splicing in pathophysiology of MGUS and MM.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15731173      PMCID: PMC1894997          DOI: 10.1182/blood-2004-10-3825

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  42 in total

1.  Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties.

Authors:  N Itano; T Sawai; M Yoshida; P Lenas; Y Yamada; M Imagawa; T Shinomura; M Hamaguchi; Y Yoshida; Y Ohnuki; S Miyauchi; A P Spicer; J A McDonald; K Kimata
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

2.  The impact of extracellular matrix on chemoresistance of solid tumors--experimental and clinical results of hyaluronidase as additive to cytostatic chemotherapy.

Authors:  G Baumgartner
Journal:  Cancer Lett       Date:  1998-09-11       Impact factor: 8.679

3.  Reported in vivo splice-site mutations in the factor IX gene: severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations.

Authors:  R P Ketterling; J B Drost; W A Scaringe; D Z Liao; J Z Liu; C K Kasper; S S Sommer
Journal:  Hum Mutat       Date:  1999       Impact factor: 4.878

4.  Intracellular localization of hyaluronan in proliferating cells.

Authors:  S P Evanko; T N Wight
Journal:  J Histochem Cytochem       Date:  1999-10       Impact factor: 2.479

5.  Serum hyaluronan in patients with multiple myeloma: correlation with survival and Ig concentration.

Authors:  I M Dahl; I Turesson; E Holmberg; K Lilja
Journal:  Blood       Date:  1999-06-15       Impact factor: 22.113

6.  Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells.

Authors:  N Itano; T Sawai; O Miyaishi; K Kimata
Journal:  Cancer Res       Date:  1999-05-15       Impact factor: 12.701

7.  In multiple myeloma, circulating hyperdiploid B cells have clonotypic immunoglobulin heavy chain rearrangements and may mediate spread of disease.

Authors:  L M Pilarski; N V Giannakopoulos; A J Szczepek; A M Masellis; M J Mant; A R Belch
Journal:  Clin Cancer Res       Date:  2000-02       Impact factor: 12.531

8.  Receptor for hyaluronan-mediated motility correlates with centrosome abnormalities in multiple myeloma and maintains mitotic integrity.

Authors:  Christopher A Maxwell; Jonathan J Keats; Andrew R Belch; Linda M Pilarski; Tony Reiman
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

9.  Overexpression of the receptor for hyaluronan-mediated motility (RHAMM) characterizes the malignant clone in multiple myeloma: identification of three distinct RHAMM variants.

Authors:  M Crainie; A R Belch; M J Mant; L M Pilarski
Journal:  Blood       Date:  1999-03-01       Impact factor: 22.113

10.  A high frequency of circulating B cells share clonotypic Ig heavy-chain VDJ rearrangements with autologous bone marrow plasma cells in multiple myeloma, as measured by single-cell and in situ reverse transcriptase-polymerase chain reaction.

Authors:  A J Szczepek; K Seeberger; J Wizniak; M J Mant; A R Belch; L M Pilarski
Journal:  Blood       Date:  1998-10-15       Impact factor: 22.113

View more
  22 in total

1.  Caution should be used in long-term treatment with oral compounds of hyaluronic acid in patients with a history of cancer.

Authors:  Procopio Simone; Migliore Alberto
Journal:  Clin Drug Investig       Date:  2015-11       Impact factor: 2.859

Review 2.  Gene Expression Profiles in Myeloma: Ready for the Real World?

Authors:  Raphael Szalat; Herve Avet-Loiseau; Nikhil C Munshi
Journal:  Clin Cancer Res       Date:  2016-11-15       Impact factor: 12.531

Review 3.  Dissecting the role of hyaluronan synthases in the tumor microenvironment.

Authors:  Alberto Passi; Davide Vigetti; Simone Buraschi; Renato V Iozzo
Journal:  FEBS J       Date:  2019-04-22       Impact factor: 5.542

4.  A genome-wide aberrant RNA splicing in patients with acute myeloid leukemia identifies novel potential disease markers and therapeutic targets.

Authors:  Sophia Adamia; Benjamin Haibe-Kains; Patrick M Pilarski; Michal Bar-Natan; Samuel Pevzner; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; John Burke; Ilene Galinsky; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Richard Stone; James D Griffin
Journal:  Clin Cancer Res       Date:  2013-11-27       Impact factor: 12.531

5.  NOTCH2 and FLT3 gene mis-splicings are common events in patients with acute myeloid leukemia (AML): new potential targets in AML.

Authors:  Sophia Adamia; Michal Bar-Natan; Benjamin Haibe-Kains; Patrick M Pilarski; Christian Bach; Samuel Pevzner; Teresa Calimeri; Herve Avet-Loiseau; Laurence Lode; Sigitas Verselis; Edward A Fox; Ilene Galinsky; Steven Mathews; Ibiayi Dagogo-Jack; Martha Wadleigh; David P Steensma; Gabriela Motyckova; Daniel J Deangelo; John Quackenbush; Daniel G Tenen; Richard M Stone; James D Griffin
Journal:  Blood       Date:  2014-02-26       Impact factor: 22.113

6.  A case of cervical cancer expressed three mRNA variant of Hyaluronan-mediated motility receptor.

Authors:  Vanessa Villegas-Ruíz; Mauricio Salcedo; Alejandro Zentella-Dehesa; Edén V Montes de Oca; Edgar Román-Basaure; Alejandra Mantilla-Morales; Víctor M Dávila-Borja; Sergio Juárez-Méndez
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

Review 7.  Biology of hyaluronan: Insights from genetic disorders of hyaluronan metabolism.

Authors:  Barbara Triggs-Raine; Marvin R Natowicz
Journal:  World J Biol Chem       Date:  2015-08-26

8.  Aberrant splice variants of HAS1 (Hyaluronan Synthase 1) multimerize with and modulate normally spliced HAS1 protein: a potential mechanism promoting human cancer.

Authors:  Anirban Ghosh; Hemalatha Kuppusamy; Linda M Pilarski
Journal:  J Biol Chem       Date:  2009-05-18       Impact factor: 5.157

Review 9.  Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Semin Cancer Biol       Date:  2008-03-26       Impact factor: 15.707

Review 10.  Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance.

Authors:  Bryan P Toole; Mark G Slomiany
Journal:  Drug Resist Updat       Date:  2008-05-19       Impact factor: 18.500

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.